Products
Gocatamig Biosimilar Trispecific Antibody (DLL3 × CD3 × Albumin) for Research
Cat No.: GMP-Bios-INN-1218
Anti-CD3E therapeutic antibody (Pre-made Gocatamig biosimilar,Trispecific Mixed scFv and Single Domains (scFvhl-VH-VH')) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Gocatamig (development codes HPN328/MK-6070) is a trispecific antibody targeting DLL3, CD3, and albumin. It is developed by Harpoon Therapeutics (now part of Merck) for neuroendocrine tumors and small cell lung cancer. It is in Phase I/II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1218-1mg | 1mg | |
| GMP-Bios-INN-1218-10mg | 10mg | |
| GMP-Bios-INN-1218-100mg | 100mg | |
| GMP-Bios-INN-1218-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Gocatamig biosimilar, Trispecific Mixed scFv and Single Domains (scFvhl-VH-VH'), Anti-CD3E;ALB;DLL3 Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody |
| INN Name | Gocatamig |
| Target | CD3E;ALB;DLL3 |
| Format | Trispecific Mixed scFv and Single Domains (scFvhl-VH-VH'); Bispecific entry |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | na;na |
| VD LC | Lambda;na |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;8z8v:B |
| Year Proposed | 2024 |
| Year Recommended | 2024 |
| Companies | Harpoon Therapeutics |
| Conditions Approved | na |
| Conditions Active | Neuroendocrine tumours;Small cell lung cancer |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
